The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997-2013

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F15%3A10312610" target="_blank" >RIV/00216208:11160/15:10312610 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S0168851015000676" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0168851015000676</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.healthpol.2015.02.016" target="_blank" >10.1016/j.healthpol.2015.02.016</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997-2013

Popis výsledku v původním jazyce

Objectives: In the Czech Republic (CZ) extensive price regulation and prescribing conditions are common instruments often employed with new drugs. Since the introduction of statins onto the market in 1990s the originally strict conditions gradually relaxed while the prescription rates and public costs were rising. The aim was to analyze long-term utilization trends of statins, changes in their reimbursement prices and prescribing conditions, and the evolution of the market. Methods: From January 1997 toDecember 2013 statin use was measured in terms of defined daily doses per 1000 insured per day (DDD/TID). The prescription-based database of the General Health Insurance Company of the Czech Republic in 1997 covering 7825,216 inhabitants, i.e. 76% of CZpopulation, was used as the administrative data source. Also the overall expenditure, unit prices, and reimbursement criteria were analyzed. Results: Between 1997 and 2013 the utilization of statins rose from 2 to 96 DDD/TID while the ex

Název v anglickém jazyce

The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997-2013

Popis výsledku anglicky

Objectives: In the Czech Republic (CZ) extensive price regulation and prescribing conditions are common instruments often employed with new drugs. Since the introduction of statins onto the market in 1990s the originally strict conditions gradually relaxed while the prescription rates and public costs were rising. The aim was to analyze long-term utilization trends of statins, changes in their reimbursement prices and prescribing conditions, and the evolution of the market. Methods: From January 1997 toDecember 2013 statin use was measured in terms of defined daily doses per 1000 insured per day (DDD/TID). The prescription-based database of the General Health Insurance Company of the Czech Republic in 1997 covering 7825,216 inhabitants, i.e. 76% of CZpopulation, was used as the administrative data source. Also the overall expenditure, unit prices, and reimbursement criteria were analyzed. Results: Between 1997 and 2013 the utilization of statins rose from 2 to 96 DDD/TID while the ex

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FQ - Veřejné zdravotnictví, sociální lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Health Policy

ISSN

0168-8510

e-ISSN

—

Svazek periodika

119

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

10

Strana od-do

1255-1264

Kód UT WoS článku

000361403000013

EID výsledku v databázi Scopus

2-s2.0-84940614294